

Marco Mancini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5514568/publications.pdf>

Version: 2024-02-01

131
papers

4,233
citations

136740

32
h-index

114278

63
g-index

133
all docs

133
docs citations

133
times ranked

4805
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3945-3950.	3.3	471
2	Epigenetic Silencing of the Myelopoiesis Regulator microRNA-223 by the AML1/ETO Oncoprotein. <i>Cancer Cell</i> , 2007, 12, 457-466.	7.7	373
3	Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 972-979.	0.8	296
4	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. <i>Blood</i> , 2005, 105, 3434-3441.	0.6	178
5	Interferon alpha-2b as therapy for Ph ⁺ -positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. <i>Blood</i> , 1988, 72, 642-647.	0.6	172
6	AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. <i>Blood</i> , 2009, 114, 3024-3032.	0.6	156
7	High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 219-228.	0.8	145
8	Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. <i>Blood</i> , 2012, 119, 4034-4046.	0.6	139
9	Therapy-related myelodysplastic syndrome acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. <i>Blood</i> , 2002, 99, 822-824.	0.6	125
10	Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia. <i>Cancer Research</i> , 2006, 66, 8903-8911.	0.4	125
11	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012, 120, 761-767.	0.6	110
12	Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. <i>Blood</i> , 2006, 107, 473-479.	0.6	109
13	MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 974-981.	0.6	99
14	Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. <i>Leukemia</i> , 2005, 19, 628-635.	3.3	85
15	Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. <i>Blood</i> , 2003, 102, 1035-1041.	0.6	74
16	NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 439-442.	1.7	74
17	BCR-ABL Antisense Oligodeoxynucleotide In Vitro Purging and Autologous Bone Marrow Transplantation for Patients With Chronic Myelogenous Leukemia in Advanced Phase. <i>Blood</i> , 1998, 91, 3156-3162.	0.6	72
18	Hematological malignancies with a deletion of 11q23: cytogenetic and clinical aspects. <i>Leukemia</i> , 1998, 12, 823-827.	3.3	69

#	ARTICLE	IF	CITATIONS
19	E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. <i>British Journal of Haematology</i> , 2003, 120, 484-487.	1.2	63
20	Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 2748-2754.	0.8	56
21	Real-life results of front-line treatment with Imatinib in older patients (>65 years) with newly diagnosed chronic myelogenous leukemia. <i>Leukemia Research</i> , 2010, 34, 1472-1475.	0.4	53
22	ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 5473-5476.	0.6	46
23	Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults. <i>Haematologica</i> , 2010, 95, 79-86.	1.7	44
24	RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. <i>Haematologica</i> , 2016, 101, 941-950.	1.7	44
25	Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission. <i>British Journal of Haematology</i> , 1995, 91, 878-884.	1.2	41
26	Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. <i>Blood</i> , 2003, 102, 2014-2020.	0.6	38
27	Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability. <i>Haematologica</i> , 2009, 94, 298-300.	1.7	38
28	Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype. <i>Leukemia</i> , 2002, 16, 1745-1751.	3.3	37
29	Characterization of a recurrent translocation t(2;3)(p15;q26) occurring in acute myeloid leukaemia. <i>Leukemia</i> , 2006, 20, 48-54.	3.3	37
30	A multiplex reverse transcriptase-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia. <i>Haematologica</i> , 2003, 88, 275-9.	1.7	36
31	Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia. <i>Leukemia</i> , 2002, 16, 2055-2061.	3.3	35
32	Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. <i>British Journal of Haematology</i> , 2003, 123, 517-521.	1.2	35
33	Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. <i>Cancer</i> , 2006, 107, 1008-1013.	2.0	28
34	Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients. <i>Leukemia</i> , 2000, 14, 364-368.	3.3	27
35	Myelodysplastic syndromes in patients under 50 years old: a single institution experience. <i>Leukemia Research</i> , 2005, 29, 749-754.	0.4	23
36	Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI-1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI-1 gene role?. <i>British Journal of Haematology</i> , 2002, 118, 438-441.	1.2	22

#	ARTICLE	IF	CITATIONS
37	Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 1017-1024.	1.7	22
38	Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. <i>Leukemia Research</i> , 2005, 29, 287-291.	0.4	20
39	Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response. <i>Leukemia and Lymphoma</i> , 2012, 53, 985-986.	0.6	20
40	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. <i>Oncotarget</i> , 2016, 7, 13886-13901.	0.8	20
41	Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome. <i>Annals of Hematology</i> , 1992, 65, 17-21.	0.8	19
42	Trisomy 14 in hematologic diseases. <i>Cancer Genetics and Cytogenetics</i> , 1993, 66, 39-42.	1.0	19
43	Is Recombinant Human Erythropoietin Treatment in Myelodysplastic Syndromes Worthwhile?. <i>Leukemia and Lymphoma</i> , 1993, 9, 79-83.	0.6	19
44	Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome. <i>Leukemia</i> , 2004, 18, 361-362.	3.3	19
45	Insertions generating the 5?RUNX1/3?CBFA2T1 gene in acute myeloid leukemia cases show variable breakpoints. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 86-91.	1.5	19
46	The EUTOS score identifies chronic myeloid leukemia patients with poor prognosis treated with imatinib first or second line. <i>Leukemia Research</i> , 2012, 36, e209-e210.	0.4	19
47	Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib. <i>Cancer Letters</i> , 2013, 333, 32-35.	3.2	19
48	Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. <i>Oncotarget</i> , 2018, 9, 7534-7540.	0.8	19
49	M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. <i>Haematologica</i> , 2008, 93, 1025-1032.	1.7	18
50	Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2006, 30, 178-182.	0.4	17
51	C-fms expression correlates with monocytic differentiation in PML-RAR $\hat{\pm}$ acute promyelocytic leukemia. <i>Leukemia</i> , 2003, 17, 98-113.	3.3	16
52	A new complex rearrangement involving theETV6,LOC115548, andMN1 genes in a case of acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 272-277.	1.5	16
53	5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. <i>Leukemia and Lymphoma</i> , 2012, 53, 1558-1560.	0.6	16
54	Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability. <i>Haematologica</i> , 2009, 94, 298-300.	1.7	16

#	ARTICLE	IF	CITATIONS
55	Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in a very high complete molecular response rate. <i>Leukemia Research</i> , 2008, 32, 255-261.	0.4	13
56	Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response. <i>Leukemia and Lymphoma</i> , 2016, 57, 99-102.	0.6	13
57	Impact of exclusion criteria for the DASISION and ENESTnd trials in the frontâ€line treatment of a â€realâ€lifeâ€™ patient population with chronic myeloid leukaemia. <i>Hematological Oncology</i> , 2017, 35, 232-236.	0.8	13
58	Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype. <i>Haematologica</i> , 2019, 104, 1168-1175.	1.7	12
59	High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. <i>Annals of Hematology</i> , 2003, 82, 476-480.	0.8	11
60	Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. <i>Leukemia Research</i> , 2005, 29, 33-39.	0.4	11
61	Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. <i>Annals of Hematology</i> , 2020, 99, 2405-2416.	0.8	11
62	Acute Myeloid Leukemias M2, Potentially Misdiagnosed as M3 Variant French-American-Britain (FAB) Subtype: A Transitional Form?. <i>Leukemia and Lymphoma</i> , 1995, 18, 49-55.	0.6	10
63	Management of Chronic Myeloid Leukemia in Chronic Phase with Autologous Stem Cell Transplantation and Alpha-2 Interferon: Cytogenetic and Clinical Results. <i>Leukemia and Lymphoma</i> , 1993, 11, 281-291.	0.6	9
64	Acute Myeloid Leukemia Secondary to a Myelodysplastic Syndrome with t(3;3) (q21;q26) in an HIV Patient Treated with Chemotherapy and Highly Active Antiretroviral Therapy. <i>Acta Haematologica</i> , 2004, 111, 160-162.	0.7	9
65	Rescue of genomic information in adult acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics: a GIMEMA centralized biological study. <i>British Journal of Haematology</i> , 2010, 149, 70-78.	1.2	9
66	Suboptimal response to imatinib according to 2006â€“2009 European LeukaemiaNet criteria: a â€grey zoneâ€™ at 3, 6 and 12â€months identifies chronic myeloid leukaemia patients who need early intervention. <i>British Journal of Haematology</i> , 2011, 152, 119-121.	1.2	9
67	Improved Overall Survival with Gemtuzumab Ozogamicin (GO) Compared with Best Supportive Care (BSC) in Elderly Patients with Untreated Acute Myeloid Leukemia (AML) Not Considered Fit for Intensive Chemotherapy: Final Results from the Randomized Phase III Study (AML-19) of the EORTC and GImema Leukemia Groups. <i>Blood</i> , 2014, 124, 619-619.	0.6	9
68	A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients. <i>Blood</i> , 2010, 116, 4848-4848.	0.6	9
69	Deletions on der(9) chromosome in adult Ph-positive acute lymphoblastic leukemia occur with a frequency similar to that observed in chronic myeloid leukemia. <i>Leukemia</i> , 2003, 17, 528-531.	3.3	8
70	Interferon alphaâ€2b as therapy for patients with Phâ€positive chronic myelogenous leukemia. <i>European Journal of Haematology</i> , 1990, 45, 25-28.	1.1	8
71	Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. <i>Annals of Hematology</i> , 2019, 98, 1919-1925.	0.8	8
72	Evolving modalities of treatment with interferon alfa-2b for Ph1-positive chronic myelogenous leukaemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, S14-S17.	0.9	7

#	ARTICLE	IF	CITATIONS
73	Molecular and cytogenetic remission in a case of subtype M4E acute myelogenous leukemia with minimal monochemotherapy: high sensitivity or spontaneous remission?. <i>European Journal of Haematology</i> , 2000, 65, 203-206.	1.1	7
74	Trisomy 13 in a patient with common acute lymphoblastic leukemia: description of a case and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2003, 144, 69-72.	1.0	7
75	Pericentric chromosome 8 inversion associated with the 5'RUNX1/3'CBFA2T1 gene in acute myeloid leukemia cases. <i>Annals of Hematology</i> , 2005, 84, 245-249.	0.8	7
76	Prolonged effect of alpha-interferon after discontinuance of treatment in chronic myelogenous leukemia patients. <i>European Journal of Haematology</i> , 2009, 43, 108-111.	1.1	7
77	A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. <i>Leukemia and Lymphoma</i> , 2011, 52, 2329-2335.	0.6	7
78	5-azacitidine in myelodysplastic syndromes with inversion of chromosome 3. <i>Leukemia</i> , 2011, 25, 736-737.	3.3	6
79	Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib. <i>British Journal of Haematology</i> , 2016, 173, 945-946.	1.2	6
80	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. <i>Hematological Oncology</i> , 2020, 38, 189-196.	0.8	6
81	Treatment of Ph ⁺ -positive chronic myelogenous leukemia (CML) with recombinant interferon alfa-2b (INTRON A). <i>Cancer Treatment Reviews</i> , 1988, 15, 21-26.	3.4	5
82	Unbalanced 6p translocation as primary karyotypic anomaly in secondary acute nonlymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1992, 60, 93-95.	1.0	5
83	The Italian External Quality Assessment Scheme in Classical Cytogenetics: Four Years of Activity. <i>Public Health Genomics</i> , 2008, 11, 295-303.	1.0	5
84	Complete Clearance of Ph ⁺ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia. <i>Acta Haematologica</i> , 2013, 129, 126-134.	0.7	5
85	Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. <i>Hematological Oncology</i> , 2017, 35, 804-809.	0.8	5
86	Ablative chemotherapy followed by peripheral blood stem cell reinfusion for chronic myelogenous leukemia in chronic phase. <i>International Journal of Cell Cloning</i> , 1992, 10, 124-126.	1.6	4
87	Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the <i>MLL/ENL</i> fusion gene. <i>American Journal of Hematology</i> , 2011, 86, 993-997.	2.0	4
88	Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials. <i>Annals of Hematology</i> , 2018, 97, 1785-1795.	0.8	4
89	Detection of BCR/ABL rearrangements in adult acute lymphoblastic leukemia using a highly sensitive interphase fluorescence in situ hybridization method (D-FISH). <i>The Hematology Journal</i> , 2001, 2, 54-60.	2.0	4
90	Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib. <i>Leukemia and Lymphoma</i> , 2011, 52, 1372-1375.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?. Hematological Oncology, 2015, 33, 48-51.	0.8	3
92	Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib. British Journal of Haematology, 2018, 181, 275-278.	1.2	3
93	Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. European Journal of Haematology, 2018, 101, 578-584.	1.1	3
94	Prognostic impact of KMT2A-AFF1 positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996. American Journal of Hematology, 2021, 96, E334-E338.	2.0	3
95	Secondary Acute non Lymphoid Leukemia in Patients Treated for non Hodgkin's Lymphoma: No Risk of Therapy-Related Anll after Provecip Schedule. Tumori, 1987, 73, 363-367.	0.6	2
96	MOLECULAR EVIDENCE OF TRANSIENT COMPLETE REMISSION AFTER AUTOGRAFTING IN Ph-/BCR REARRANGED CHRONIC MYELOGENOUS LEUKAEMIA. British Journal of Haematology, 1989, 72, 285-286.	1.2	2
97	Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status. Leukemia, 2005, 19, 287-289.	3.3	2
98	ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012072.	0.5	2
99	Incidence of Clinically Significant (≥ 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. Oncology Research and Treatment, 2019, 42, 660-664.	0.8	2
100	Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance. Leukemia and Lymphoma, 2020, 61, 3476-3483.	0.6	2
101	Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,. Blood, 2011, 118, 3783-3783.	0.6	2
102	Prognostic Impact of t(4;11)(q21;q23)/KMT2A-AFF1-Positivity in 926 BCR-ABL1-Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996. Blood, 2019, 134, 1469-1469.	0.6	2
103	Similar mechanisms formed ring markers containing chromosome 12 pericentromeric region in two patients with therapy-related acute myeloid leukemia. Cancer Genetics and Cytogenetics, 2008, 181, 131-137.	1.0	1
104	Deletions of the Derivative Chromosome 9 Do Not Influence Response to Imatinib of Early Chronic Phase Chronic Myeloid Leukemia Patients (A GIMEMA Working Party Analysis).. Blood, 2006, 108, 2112-2112.	0.6	1
105	Exclusion Criteria In The Dasison and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a "Real-life" Patient Population With Chronic Myelogenous Leukemia?. Blood, 2013, 122, 4002-4002.	0.6	1
106	Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?. Blood, 2015, 126, 4038-4038.	0.6	1
107	Incidence of Severe (≥ 10 g/dl) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy. Blood, 2016, 128, 1903-1903.	0.6	1
108	Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood, 1988, 72, 642-647.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. <i>Blood</i> , 2016, 128, 5544-5544.	0.6	1
110	Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-€positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	1
111	P066 Familiar occurrence of myelodysplastic syndrome with del(5q). <i>Leukemia Research</i> , 2009, 33, S97-S98.	0.4	0
112	Familial occurrence of myelodysplastic syndrome with del(5q). <i>Leukemia and Lymphoma</i> , 2011, 52, 1143-1145.	0.6	0
113	Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients. <i>American Journal of Hematology</i> , 2015, 90, E95-E96.	2.0	0
114	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e328-e333.	0.2	0
115	Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2261-2266.	0.6	0
116	Identification of a LOH Region on Chromosome 9p Associated with a Specific Gene Expression Signature in Adult B-Lineage ALL through Integration of High Density Microarray Expression and SNP Analyses.. <i>Blood</i> , 2004, 104, 1119-1119.	0.6	0
117	Long Term Follow up on Patients with Ph-Abnormal Clones Emerged during Imatinib Therapy.. <i>Blood</i> , 2006, 108, 2116-2116.	0.6	0
118	Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.. <i>Blood</i> , 2006, 108, 2158-2158.	0.6	0
119	Acute Erythroid Leukemia: A Distinctive Subtype of AML? Outcome and Prognostic Factors in Comparison with Non-M6 AML. The Gimema Experience.. <i>Blood</i> , 2009, 114, 1019-1019.	0.6	0
120	Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia: How Important is the Achievement of Complete Cytogenetic Response after 3 Months?. <i>Blood</i> , 2009, 114, 4271-4271.	0.6	0
121	Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).. <i>Blood</i> , 2009, 114, 1777-1777.	0.6	0
122	Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib. <i>Blood</i> , 2012, 120, 3769-3769.	0.6	0
123	Whole Transcriptome Sequencing In Refractory T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 350-350.	0.6	0
124	Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 3687-3687.	0.6	0
125	Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects. <i>Blood</i> , 2014, 124, 5326-5326.	0.6	0
126	Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials. <i>Blood</i> , 2016, 128, 2847-2847.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?. Blood, 2018, 132, 1746-1746.	0.6	0
128	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?. Blood, 2018, 132, 5516-5516.	0.6	0
129	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort. Blood, 2018, 132, 5464-5464.	0.6	0
130	Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia. Blood, 2021, 138, 1486-1486.	0.6	0
131	The Italian National External Quality Assessment Program in Cytogenetics: 4 years of activity (2013-2016) following the introduction of poor performance criteria. Annali Dell'Istituto Superiore Di Sanita, 2018, 54, 109-116.	0.2	0